ACT Advisors’s AN2 Therapeutics ANTX Stock Holding History

ACT Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,199	Closed	-$16.8K	–	67
2025 Q3	$16.8K	Buy	+13,199	New	+$15.1K	0.01%	70

Other funds holding ANTX

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACT Advisors's ANTX Position: Q4 2025 in Review

ACT Advisors sold out of AN2 Therapeutics (ANTX) in Q4 2025, closing a stake of 13,199 shares — an estimated $16.8K sold.

ACT Advisors first reported a position in ANTX in Q3 2025 and held it in 1 quarter. The position peaked at $16.8K in Q3 2025. 37 funds tracked by Wall St. Rank hold ANTX as of Q4 2025.

ACT Advisors reported no remaining AN2 Therapeutics position as of Q4 2025 after selling out during the quarter.
ACT Advisors sold 13,199 AN2 Therapeutics shares in Q4 2025, an estimated $16.8K.
ACT Advisors first reported a position in AN2 Therapeutics in Q3 2025 and held it in 1 quarter.
ACT Advisors's AN2 Therapeutics position peaked at $16.8K in Q3 2025.
37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q4 2025.

Based on ACT Advisors's 13F filing for Q4 2025, filed 14 Jan 2026.